The current P/S multiple suggests that investors are pricing in a successful FDA approval and subsequent U.S. commercialization, effectively ignoring the company's lack of earnings. This valuation is highly sensitive to regulatory timelines, and any delay in the DREAM study outcomes could lead to a significant compression of this multiple as the market recalibrates for execution risk.

The persistent negative ROIC trend highlights the difficulty of scaling a high-fixed-cost medical device business in a pre-profit phase. Without a clear path to positive operating margins, the company's ability to compound capital remains compromised, and investors should monitor whether future U.S. revenue can offset the heavy R&D and SG&A burden currently depressing returns.

The extreme volatility in the cash conversion cycle indicates that the company's operational efficiency is not yet optimized, likely due to the complexities of managing a specialized medical device supply chain. Investors should be wary of these swings, as they may mask underlying issues in inventory turnover or potential delays in hospital reimbursement cycles.

This compression in liquidity suggests that the company is approaching a point where external financing will be required to maintain operations. The reliance on current assets to fund ongoing losses leaves little margin for error, and any unexpected operational or regulatory setback could force a dilutive capital raise under unfavorable market conditions.